DETAILED ACTION
Claims 1-8 are currently pending and rejected.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Response to Amendment and Arguments
Applicant's amendment and arguments filed 13 July 2026 have been fully considered and entered into the instant application. The amendment filed 13 July 2026 added new claim 8 which is included in the following 35 USC 103 rejection. In regards to the 35 USC 102(a)(1) rejection, Applicant’s representative argues that:
PNG
media_image1.png
86
652
media_image1.png
Greyscale
. Please see MPEP 2121 which provides that:
PNG
media_image2.png
104
612
media_image2.png
Greyscale
Applicant’s representative argues that the art is highly unpredictable, there is no working examples or prophetic examples, and Skouras 2016 does not provide any direction or procedures on how to carry out the claimed invention. These arguments are not persuasive as SKOURAS provides direction in how to carry out the claimed invention in that Olatec has demonstrated in a large number of preclinical in vitro and animal efficacy studies that dapansutrile inhibits IL-1β with significance, that dapansutrile is orally active small molecule with a 24-hour half-life providing a safety benefit over the biologics while allowing for attractive once-a-day dosing, dapansutrile is in phase 2 clinical trials in two dosage forms (page 2/4) and that there are plans to initiate preclinical programs for oral dapanustrile in Parkinson’s Disease (page 4). In regards to the unpredictability, Applicant’s representative argues that references discussing pioglitazone and inosine, NLRP3 inhibitors, failed to treat PD. These arguments are not persuasive as pioglitazone is:
PNG
media_image3.png
94
198
media_image3.png
Greyscale
, and inosine is
PNG
media_image4.png
222
242
media_image4.png
Greyscale
, whereas the structure of dapansutrile is
PNG
media_image5.png
152
198
media_image5.png
Greyscale
. Please note that these structures are not similar as dapansutriled doe not contain any heterocylic or heteroaromatic rings and both pioglitazone and inosine have multiple rings in their structure. Besides the lack of structural similarity, additionally, as seen in Lancet Neurol 2015; 14(8): 795-803, provided by applicant, in regards to the trials with pioglitazone, the data provided is only for two doses, page 8, and it is possible that the beneficial effect of pioglitazone was missed owing to the pitfalls of the study design, including the choice of the primary outcome measure. As seen in JAMA, 2021; 326(10): 926-939 (provided by applicant), in regards to the trials with inosine, page 936 the study has several limitaitons, the lack of evidence for benefit of inosine treatment on PD progression for 1 to 20 ears shortly after diagnosis, when most dopaminergic neurons may have already degenerated, the use of urate precursor inosine rather than urate, the lack of demonstrated efficacy also does not exclude the possibility of benefit in a small subpopulation of patients with PD. In regards to the lack of working examples or prophetic examples, as seen in MPEP 2164.02, the compliance with the enablement requirement does not turn on whether an example is disclosed. The 35 USC 102(a)(1) rejection is therefore maintained.
In regards to the 35 USC 103 rejection, Applicant argues that contrary to SKOURAS, applicant’s application provides an enabling disclosure as example 2 shows dapansutrile improves the locomotor deficits in mice in an experimental PD model. This argument is not persuasive as discussed above in response to the arguments of the 35 USC 102(a)(1) rejection, SKOURAS is an enabling disclosure as efficacy is not a requirement for prior art enablement and examples are also not a requirement, see MPEP 2122 and 2164.02. Additionally, SKOURAS provides direction in how to carry out the claimed invention in that Olatec has demonstrated in a large number of preclinical in vitro and animal efficacy studies that dapansutrile inhibits IL-1β with significance, that dapansutrile is orally active small molecule with a 24-hour half-life providing a safety benefit over the biologics while allowing for attractive once-a-day dosing, dapansutrile is in phase 2 clinical trials in two dosage forms (page 2/4) and that there are plans to initiate preclinical programs for oral dapanustrile in Parkinson’s Disease (page 4). The 35 USC 103 rejection is therefore maintained.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 1 and 3 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by SKOURAS, DAMARIS et al. Damaris Skouras-CEO of Olatec on Treating inflammation, 23 December 2016, pages 1-4, retrieved from https://www.onemednews.com/2016/12/23/damaris-scours/, Cite No. 9, IDS filed 9/12/2025, (SKOURAS).
Applicant’s instant claim 1 is drawn to the treatment of Parkinson’s disease by administering dapansutrile.
SKOURAS provides the treatment of Parkinson’s disease by the administration of dapansutrile as SKOURAS provides that Parkinson’s disease shares a common causative pathway with other inflammatory diseases in which the end result is the production of a pro-inflammatory protein (or cytokine) called Interleukin-1, which includes IL-1β and that dapansutrile inhibits IL-1B with significance SKOURAS provides that dapansutrile is in Phase 2 clinical trials in two dosage forms, topical gel and an oral capsule. Additionally, plans to initiate preclinical programs for oral dapansutrile in several chronic diseases in 2017, including Parkinson’s Disease.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 1-8 is/are rejected under 35 U.S.C. 103 as being unpatentable over SKOURAS, DAMARIS et al. Damaris Skouras-CEO of Olatec on Treating inflammation, 23 December 2016, pages 1-4, retrieved from https://www.onemednews.com/2016/12/23/damaris-scours/, Cite No. 9, IDS filed 9/12/2025, (SKOURAS), in view of BERTINARIA, MASSIMO et al., Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity, Archives of Biochemistry and Biophysics, 16 November 2018, pages 116-139, vol. 670, ELSEVIER, US. (BERTINARIA), 1449 filed 9/12/2025, Cite No. 6, further in view of MARCHETTI, CARLO et al. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation, Proceedings of the National Academy of Sciences of the United States of America (PNAS), 29 January 2018, IDS filed 9/12/2025, Cite No. 3, (MARCHETTI) and further in view of WO2019/182981.
SKOURAS provides that Parkinson’s disease shares a common causative pathway with other inflammatory diseases in which the end result is the production of a pro-inflammatory protein (or cytokine) called Interleukin-1, which includes IL-1β and that dapansutrile inhibits IL-1B with significance SKOURAS provides that dapansutrile is in Phase 2 clinical trials in two dosage forms, topical gel and an oral capsule. Additionally, plans to initiate preclinical programs for oral dapansutrile in several chronic diseases in 2017, including Parkinson’s Disease.
BERTINARIA provides that the overexpression of NLRP3 and the activation of the NLRP3-mediated inflammatory response has been observed in recent years in several neurodegenerative diseases such as Parkinson’s disease, page 117. In BERTINARIA it is seen that dapansutrile is useful for the treatment of inflammation as seen by the development for the treatment of osteoarthritis of the knee, page 132. BERTINARIA provides the compound OLT 1177 (dapansutrile) on page 134, Figure 23 a):
PNG
media_image6.png
88
156
media_image6.png
Greyscale
. Page 133 provides that OLT177 (dapansutrile) has potent NLRP3 inhibition from covalent inhibition at the protein level.
MARCHETTI provides OLT1177 is a selective inhibitor of the NLRP3 inflammazome that is safe at oral doses up to 1000mg each day for 8 days with no clinical, hematological, or organ toxicities observed and has potential for the treatment of IL-1β- and IL-18-mediated diseases, page E1530. Marchetti provides on page E1530 that pharmacologic inhibition or genetic deficiency of NLRP3 results in markedly reduced inflammation in animal models of human disease.
WO2019/182981 provides pharmaceutical compositions with the active compound of dapansutrile in an amount of about 0.1-5% for an injectable formulation, and additional tablet formulation, capsule formulation, topical formulation, and patch formulation. Page 3 provides that dapansutrile is a selective NLRP3 inflammasome inhibitor and inhibits the production of mature IL-1β and IL-18 in mice and in human cells in vitro. Through this mechanism of action, dapansutrile prevents production and/or release of IL-1β and inhibits the formation of NLRP3 inflammasome in animals and human subjects.
As provided in SKOURAS, dapansutrile is useful for the treatment of Parkinson’s disease as Parkinson’s disease pathway includes IL-1β and that dapansutrile inhibits IL-1B with significance SKOURAS provides that dapansutrile is in Phase 2 clinical trials in two dosage forms, topical gel and an oral capsule with plans to initiate preclinical programs for oral dapansutrile in several chronic diseases in 2017, including Parkinson’s Disease. While SKOURAS does not provide systemic administration and does not specifically provide the improvement of a movement related symptom such as shaking, rigidity, slowness of movement, difficulty with fine motor skills, walking, and gait, as seen in MARCHETTI and WO2019/182981, dapansutrile can be administered orally and via an injectable formulation. In regards to the improvement of a movement related symptom of Parkinson’s Disease, while the specific symptoms claimed are not mentioned in the prior art references, SKOURAS provides that dapansutrile targets a central cause of inflammation and is useful for the treatment of inflammation. Additionally, as in BERTINARIA, it is seen that dapansutrile is useful for the treatment of inflammation as seen by the development for the treatment of osteoarthritis of the knee, page 132. Marchetti provides on page E1530 that pharmacologic inhibition or genetic deficiency of NLRP3 results in markedly reduced inflammation in animal models of human disease. This provided treatment/reduction of inflammation would provide an improvement of a movement related symptom such as slowness of movement, walking, and gait. In regards to new claim 8, as seen by Marchetti, OLT1177 is safe at oral doses up to 1000mg each day.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA L ANDERSON whose telephone number is (571)272-0696. The examiner can normally be reached Monday-Friday from 6am-2pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/REBECCA L ANDERSON/Primary Examiner, Art Unit 1626 ____________________ 14 September 2026
Rebecca Anderson
Primary Examiner
Art Unit 1626, Group 1620
Technology Center 1600